-

Shareholder Alert: Robbins LLP Announces United States Oil Fund, LP (USO) Sued for Misleading Shareholders

SAN DIEGO & WALNUT CREEK, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of United States Oil Fund, LP (NYSEArca: USO) filed a class action complaint against the Fund for alleged violations of the Securities Exchange Act of 1934 between March 19, 2020 and April 28, 2020. USO is an exchange traded fund (“ETF”) purportedly designed to track the daily changes in percentage terms of the spot price of West Texas Intermediate (“WTI”) light, sweet crude oil delivered to Cushing, Oklahoma.

If you suffered a loss as a result of USO's misconduct, click here.

United States Oil Fund, LP (USO) Accused of Misleading Shareholders

According to the complaint, in early 2020, the demand for oil fell precipitously as governments imposed lockdowns and business halted operations in response to the coronavirus pandemic. Rather than disclosing the risks these conditions presented to the Fund, USO conducted a massive offering in March 2020, selling billions of dollars' worth of USO shares to the market. After the offering, USO began to suffer extraordinary losses. Consequently, throughout April, USO made significant changes to its investment strategy to mitigate the market's negative impact on the Fund until it was fundamentally different from the strategy detailed in its offering's registration statement. Despite efforts to improve the Fund's position, by April 28, 2020, USO closed at $2.13 per share, down over 60% since March 19, 2020. Finally, on May 6, 2020, USO disclosed that the 2020 market conditions that had caused severe damage to investors had materially impacted the Fund before its March 2019 offering, but was omitted from USO's registration statement. Consequently, on May 29, 2020, the SEC and the Commodity Futures Trading Commission launched investigations into USO regarding the Fund’s disclosures to investors and the Fund’s rapid-fire changes to its investment strategy.

United States Oil Fund, LP (USO) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against USO settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NYX:USO

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom